Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

0 avis

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Archive ouverte

Edité par CCSD ; Elsevier -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

Archive ouverte | Mazieres, Julien | CCSD

International audience. Importance MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 ( MET ex14)-skipping non–small cell lung cancer (NSCLC); however, data with longer follow-u...

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Archive ouverte | Solomon, Benjamin | CCSD

International audience

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Archive ouverte | Solomon, Benjamin | CCSD

International audience. PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung canc...

Chargement des enrichissements...